What Does MindWalk's (NASDAQ:HYFT) Multi-Year Agreement with Teva Australia Mean for Its AI Drug Discovery Platform?

Sonal Goyal

05 November 2026 12:37 PM AEDT

What Does MindWalk's (NASDAQ:HYFT) Multi-Year Agreement with Teva Australia Mean for Its AI Drug Discovery Platform?

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Key Highlights

• MindWalk signed a multi-year agreement with Teva Pharmaceuticals Australia to deploy ReefIQ and LensAI capabilities for antibody-discovery work

• The collaboration builds on a working relationship between MindWalk and Teva Australia that dates back to 2018

• ReefIQ operates on HYFT Technology, a biological representation encompassing 660 million patterns and 25 billion relationships

• The agreement represents a recurring-revenue platform relationship rather than a one-time service engagement

MindWalk Holdings Corp. (NASDAQ:HYFT), a Bio-Native AI company, announced a multi-year agreement with Teva Pharmaceuticals Australia Pty Ltd to deploy its ReefIQ platform and specified LensAI analytical capabilities in support of defined antibody-discovery workflows. The agreement extends a collaboration between the two companies that has been ongoing since 2018.

Details of the Agreement

Under the terms of the arrangement, MindWalk will deploy ReefIQ, its HYFT-powered biological context layer, along with specified LensAI analytical capabilities to support a defined scope of antibody-discovery work for Teva Australia. The platform will enable Teva Australia's scientists to use AI capabilities in support of discovery decisions, generating predictions to accelerate antibody design optimization.

MindWalk will provide authorized analysis of approved data sources within the agreed scope, with deployment and use governed by Teva Australia's applicable information-security, privacy, data-governance, scientific-review, and human-oversight requirements. Financial terms of the agreement were not disclosed.

The ReefIQ Platform and HYFT Technology

ReefIQ is MindWalk's biological context layer for life sciences, built on its proprietary HYFT Technology. The underlying platform encompasses 660 million biological patterns and 25 billion relationships, refined over 20 years of curation. ReefIQ organizes and governs connected biological context drawn from agreed sources, including sequences, structures, assay outputs, literature, evidence, provenance, and program history.

LensAI, MindWalk's reasoning and application layer, operates over this context alongside client-selected models or agents, subject to each client's integration, deployment, governance, and human-review requirements. As new data and relationships are added, updated context becomes available under the client's governance framework, while prior results remain queryable where authorized.

Jennifer Bath, PhD, President and CEO of MindWalk, noted that the constraint in antibody discovery has shifted from generating data to connecting and governing that data, carrying what program teams learn from one phase to the next. Anthony Doyle, Vice President of Antibody Discovery at Teva Australia, emphasized that the value lies in pairing computational insight with deep biological expertise and experimental validation.

Revenue Model and Business Significance

For MindWalk, the Teva Australia agreement represents the type of recurring-revenue platform relationship the company has communicated to the market. The company has distinguished ReefIQ deployments from both fee-for-service projects, which end when the deliverable is shipped, and conventional software subscriptions priced by the seat. A ReefIQ deployment is structured as a multi-year platform relationship with recurring revenue, supporting scientists as programs advance within the agreed scope. MindWalk indicated it is in active discussions with additional life sciences organizations regarding further ReefIQ deployments.

The Road Ahead

MindWalk's multi-year agreement with Teva Australia establishes a defined deployment of its AI-driven antibody discovery platform within a major pharmaceutical company's workflow. The deal's structure as a recurring-revenue relationship, rather than a one-off project, aligns with MindWalk's stated strategy of building long-term platform partnerships across the life sciences industry. As the company pursues additional ReefIQ deployments, the commercial traction of these agreements will be a key indicator of the platform's adoption trajectory.

FAQs

Q: What will MindWalk's ReefIQ platform be used for under this agreement?

A: ReefIQ and its LensAI capabilities will be deployed to support defined antibody-discovery workflows for Teva Australia, helping scientists generate predictions and accelerate antibody design optimization.

Q: How long have MindWalk and Teva Australia been collaborating?

A: MindWalk has been collaborating with Teva Australia since 2018, and this multi-year agreement extends that existing relationship.

Q: What is HYFT Technology?

A: HYFT Technology is MindWalk's proprietary biological representation encompassing 660 million patterns and 25 billion relationships, refined over 20 years of curation, which powers the ReefIQ platform.

Q: Were the financial terms of the agreement disclosed?

A: No, the financial terms of the multi-year agreement were not disclosed.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.